Hagens Berman Warns Investors of Soleno Therapeutics Class Action Over Drug Launch Issues

Hagens Berman Highlights Soleno Therapeutics Class Action Alert

Investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) are being urged by the law firm Hagens Berman to take note of a significant class action lawsuit concerning alleged misconduct related to the launch of the company's critical drug for managing Prader-Willi syndrome (PWS). This alert comes as the firm emphasizes that the deadline to participate in this legal action is approaching fast, with a lead plaintiff deadline set for May 5, 2026.

Overview of the Allegations

Soleno Therapeutics is facing allegations that it misrepresented the safety and commercial viability of its flagship drug, VYKAT™ XR (DCCR). Investors who purchased the company's stock between March 26, 2025, and November 4, 2025, and experienced considerable losses are particularly affected. The lawsuit is centered around claims that Soleno did not adequately disclose critical information regarding safety risks associated with DCCR, including serious concerns such as fluid retention and risks of heart failure in children administered the drug. Furthermore, the integrity of the data from clinical trials has been called into question, raising significant red flags about the company's marketing practices.

Leading the investigation for Hagens Berman, Reed Kathrein pointed out that the lawsuit focuses on troubling claims that Soleno misled investors by presenting inflated metrics related to the drug's launch. In what was described as an artificial boost, the company allegedly inflated launch figures through manipulative practices rather than legitimate market demand.

Consequences of Allegations

The situation escalated dramatically in August 2025, when a report published by activist short seller Scorpion Capital opened the floodgates for scrutiny. The report stated that there were widespread adverse reactions from patients treated with DCCR, leading to an immediate drop in Soleno's stock price. Just a few months later, on November 4, 2025, Soleno publicly admitted to major disruptions in the launch of DCCR, resulting in a shocking 27% plummet in stock value on the announcement day.

What Investors Should Do

Those who have suffered losses from investing in Soleno's stock during the class period are encouraged to take immediate action. They have until May 5, 2026, to file a petition with the court, moving to serve as lead plaintiff in this significant case. Hagens Berman provides interested investors with the opportunity to report their loss and assist in the ongoing investigation.

The firm also invites whistleblowers with non-public information regarding Soleno's activities to reach out. Under the SEC's Whistleblower Program, tip-offs can potentially lead to rewards of up to 30 percent from any successful recovery achieved by the SEC.

About Hagens Berman

Hagens Berman is recognized as a leading plaintiff-side law firm, focusing on complex litigation aimed at ensuring corporate accountability. The firm has a proven record, securing over $2.9 billion for their clients across various cases of corporate wrongdoing. Their expertise in representing investors continues to shine, further solidified by this latest action against Soleno Therapeutics.

In conclusion, the unfolding events surrounding Soleno Therapeutics serve as a crucial reminder for investors about the importance of due diligence and the potential legal avenues available when corporate misconduct occurs. Interested parties are encouraged to stay informed and consider their options wisely, especially given the rapidly approaching deadline.